作者
Nobuhisa Ishiguro,Naoko Koseki,Miki Kaiho,Tadashi Ariga,Hídeaki Kikuta,Koji Oba,Takehiro Togashi,Keisuke Morita,Akira Inagawa,Atsushi Okamura,Shigeru Yamazaki,Satoru Shida,Mutsuko Konno,Nobuaki Kawamura,Akitoshi Ishizaka,Kohei Takada,Keiji Tsubakihara,Naoko Nagano,M Shibata,Hiroaki Furuyama,Yoshihiro Matsuzono,Akemi Koike,Mari Murashita,Yoshio Hatae,Hideki Arioka,Tatsuru Yamanaka,Tôru Watanabe,Yuuichi Tabata,Yoshihiro Kumita,Kyosuke Hazama,Yasushi Akutsu,Hayato Aoyagi,Chie Tobise,Katsuki Azuma,Kohichi Yasoshima,Yoko Sawada,Kazuyuki Uetsuji,Akira Tsuchida,Akira Tsuchiyama,Kazue Yasuda,Yasuhisa Odagawa,Masaharu Yoshioka
摘要
The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014–2015 to 2016–2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p < 0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p < 0.001). A logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients (p < 0.001). The number of biphasic fever episodes in influenza A- or B-infected patients aged 0–4 years was 2.89-times greater than that in patients aged 10–18 years (p = 0.010), and the number of episodes in influenza A- or B-infected patients aged 5–9 years was 2.13-times greater than that in patients aged 10–18 years (p = 0.012).